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Abstract
Background: The benefits and risks of anti-acid medication in patients with idiopathic pulmonary fibrosis (IPF)
remain a topic of debate. We investigated whether use of anti-acid medication at baseline was associated with
differences in the natural course of disease or influenced the treatment effect of nintedanib in patients with IPF.
Methods: Post-hoc analyses of outcomes in patients receiving versus not receiving anti-acid medication
(proton pump or histamine-2 receptor inhibitor) at baseline using pooled data from the two Phase III randomized
placebo-controlled INPULSIS® trials of nintedanib in patients with IPF.
Results: At baseline, 406 patients were receiving anti-acid medication (244 nintedanib; 162 placebo) and 655 were not
(394 nintedanib; 261 placebo). In an analysis of the natural course of IPF by anti-acid medication use at baseline, the
adjusted annual rate of decline in FVC was − 252.9 mL/year in placebo-treated patients who were receiving anti-acid
medication at baseline and − 205.4 mL/year in placebo-treated patients who were not (difference of − 47.5 mL/year
[95% CI: –105.1, 10.1]; p = 0.1057). In an analysis of the potential influence of anti-acid medication use on the treatment
effect of nintedanib, the adjusted annual rates of decline in FVC were − 124.4 mL/year in the nintedanib group and −
252.9 mL/year in the placebo group (difference of 128.6 mL/year [95% CI: 74.9, 182.2]) in patients who were receiving
anti-acid medication at baseline and − 107.0 mL/year in the nintedanib group and − 205.3 mL/year in the placebo
group (difference of 98.3 mL/year [95% CI: 54.1, 142.5]) in patients who were not (treatment-by-time-by-subgroup
interaction p = 0.3869). The proportions of patients who had ≥1 investigator-reported acute exacerbation were 11.7%
and 5.0% in placebo-treated patients, and 4.9% and 4.8% of nintedanib-treated patients, among patients who were
and were not receiving anti-acid medication at baseline, respectively.
Conclusions: In post-hoc analyses of data from the INPULSIS® trials, anti-acid medication use at baseline was
not associated with a more favorable course of disease, and did not impact the treatment effect of nintedanib, in
patients with IPF.
Trial registration: ClinicalTrials.gov identifiers: NCT01335464 and NCT01335477.
Background
Idiopathic pulmonary fibrosis (IPF) is a specific form of
progressive fibrosing interstitial lung disease character-
ized by worsening lung function and dyspnea [1]. IPF is
believed to develop as a result of an aberrant wound
healing response to epithelial injury, in which activated
alveolar epithelial cells release fibrogenic growth factors,
promoting fibroblast proliferation and transformation to
myofibroblasts and excess deposition of extracellular
matrix [2]. IPF typically presents during the sixth or sev-
enth decade and is more common in men than in
women [1]. The natural history of IPF is variable but its
prognosis is poor [3]. Acute deteriorations in respiratory
function, known as acute exacerbations, are a common
feature of the clinical course of IPF and a major cause of
morbidity and mortality [4].
Gastroesophageal reflux disease (GERD) is known to
be a common comorbidity in patients with IPF, but its
reported prevalence varies widely according to the defin-
ition used [5]. In the INSIGHTS-IPF registry of patients
with IPF in Germany, 29% of patients reported GERD
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on enrollment [6], while in a prospective study of 65 pa-
tients with IPF, acid gastroesophageal reflux occurred in
87% of patients subjected to 24-h pH monitoring [7]. It
has been hypothesized that microaspiration caused by
GERD plays a role in the pathogenesis of IPF by causing
injury to the lung epithelium and the initiation of in-
flammatory cascades [8–11] but a causal relationship be-
tween GERD and IPF has not been established.
Proton pump inhibitors used to treat GERD have
pleiotropic antioxidant and anti-inflammatory effects
[12]. Proton pump inhibitors target the H+/K+ ATPase,
which has recently been shown to be expressed in the
hyperplastic alveolar epithelium in patients with IPF
[13]. Use of anti-acid medication has been associated
with a decreased rate of decline in FVC and improved
survival in some observational studies in patients with
IPF [14, 15]. Surgical intervention to treat GERD
(i.e. Nissen fundoplication) in patients with IPF has also
been associated with improved survival [14, 16]. The latest
international clinical practice guidelines for IPF included a
conditional recommendation for the use of anti-acid ther-
apy in patients with asymptomatic GERD, based on very
low quality evidence [17]. However, there are no data from
randomized controlled trials showing an improvement in
outcomes in patients with IPF treated with anti-acid medi-
cation and the benefits and risks of anti-acid medication
in patients with IPF remain a topic of debate [18–20].
Nintedanib is an intracellular inhibitor of tyrosine ki-
nases that has been approved for the treatment of IPF in
many countries and regions, including the US, Europe
and Asia. In the latest international clinical practice
guidelines for IPF [17], nintedanib received a conditional
recommendation for use based on data from three ran-
domized controlled trials [21, 22]. In the two replicate
Phase III INPULSIS® trials, nintedanib slowed disease
progression in patients with IPF by reducing the rate of
decline in forced vital capacity (FVC) by about 50% [22].
The most frequently reported adverse events in patients
treated with nintedanib were gastrointestinal, particu-
larly diarrhea.
We conducted post-hoc analyses of data from the
INPULSIS® trials to investigate whether use of anti-acid
medication at baseline was associated with differences in
the natural course of disease or influenced the treatment
effect of nintedanib in patients with IPF.
Methods
The design of the INPULSIS® trials has been described
[22]. Briefly, participants had to have been diagnosed
with IPF within the previous 5 years and to have an FVC
of ≥50% predicted and a diffusing capacity of the lungs
for carbon monoxide (DLco) of 30–79% predicted. In
the absence of a surgical lung biopsy, patients were re-
quired to have honeycombing and/or a combination of
traction bronchiectasis and reticulation in the absence of
atypical features of usual interstitial pneumonia on
high-resolution computed tomography (HRCT). Patients
were randomized 3:2 to receive nintedanib 150 mg bid
or placebo for 52 weeks, with a follow-up visit 4 weeks
later. The primary endpoint was the annual rate of de-
cline in FVC (mL/year), analyzed using a random coeffi-
cient regression model including sex, age and height as
covariates. Key secondary endpoints were time to first
investigator-reported acute exacerbation (defined in
[22]) and change from baseline in St George’s Respira-
tory Questionnaire (SGRQ) total score, both over
52 weeks. Time to first acute exacerbation was analyzed
using the log rank test, with hazard ratios and confi-
dence intervals obtained using the Cox’s proportional
hazards model adjusted for sex, age and height. Change
from baseline in SGRQ total score was analyzed using a
mixed model for repeated measures including treatment
and visit as fixed effects, baseline score as a covariate,
and treatment-by-visit and baseline score-by-visit as
interaction terms.
The post-hoc analyses presented in this paper were
based on pooled data from both INPULSIS® trials and
included all patients who received ≥1 dose of study drug.
Anti-acid medications comprised proton pump inhibi-
tors and histamine-2 receptor antagonists. Patients who
took anti-acid medication before and also after the first
intake of trial medication (based on case report forms)
were considered to be using anti-acid medication at
baseline. The presence of GERD was assessed solely
based on the comorbidities reported by the patient and
provided in the case report form.
To evaluate whether anti-acid medication use at base-
line was associated with differences in the natural course
of IPF, analyses of the annual rate of decline in FVC
(mL/year) and the time to absolute decline in FVC ≥10%
predicted or death over 52 weeks were conducted in pa-
tients treated with placebo who were versus were not re-
ceiving anti-acid medication at baseline. A Cox
regression model with terms for trial, subgroup, sex, age
and height was used to assess time to absolute decline in
FVC ≥10% predicted or death over 52 weeks. The ori-
ginal statistical approach for the annual rate of decline
in FVC was repeated, but with an interaction term
time-by-baseline anti-acid medication use included as a
fixed effect in the model.
To evaluate the potential influence of anti-acid medi-
cation at baseline on the treatment effect of nintedanib,
analyses of the annual rate of decline in FVC (mL/year),
time to first investigator-reported acute exacerbation,
change from baseline in SGRQ total score, time to abso-
lute decline in FVC ≥5% predicted or death, or FVC
≥10% predicted or death, over 52 weeks were conducted
in patients who were versus were not receiving anti-acid
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medication at baseline. For the annual rate of decline in
FVC, the term subgroup and the interaction terms
treatment-by-subgroup, time-by-subgroup and treatment-
by-time-by-subgroup were included in the original model.
For time to first investigator-reported acute exacerbation
and change from baseline in SGRQ total score, the term
subgroup and the interaction term treatment-by-subgroup
were included in the model. Time to absolute decline in
FVC ≥5% predicted or death, or FVC ≥10% predicted or
death was analyzed using a Cox regression model with the
term subgroup and the interaction term treatment-by-
subgroup included in the model. The interaction p-value
is an indicator of the potential difference in the treatment
effect of nintedanib versus placebo between the sub-
groups. Statistical Analysis System (SAS) version 9.4 was
used for all the analyses.
Safety was assessed via clinical and laboratory evalu-
ation and the recording of adverse events with onset
after the first dose and up to 28 days after the last dose
of study drug. Adverse events were coded according to
the Medical Dictionary for Regulatory Activities version
16.1. Safety analyses were descriptive.
Results
Patients
A total of 406 (38%) patients were receiving anti-acid
medication at baseline (244 in the nintedanib group, 162
in the placebo group) and 655 patients were not (394 in
the nintedanib group, 261 in the placebo group). Of the
patients receiving anti-acid medication at baseline, 226
(93%) in the nintedanib group and 147 (91%) in the pla-
cebo group were receiving ≥1 proton pump inhibitor; 25
patients (10%) in the nintedanib group and 22 patients
(14%) in the placebo group were receiving ≥1 histamine-2
receptor antagonist (Additional file 1).
Baseline characteristics were generally similar between
the subgroups by use of anti-acid medication use at base-
line, but a greater proportion of White than Asian patients
were receiving anti-acid medication and SGRQ total score
was higher (indicating worse quality of life) in patients re-
ceiving anti-acid medication (Table 1). Of the patients re-
ceiving anti-acid medication at baseline, 52.0% and 51.2%
of patients in the nintedanib and placebo groups, respect-
ively, reported having GERD (Additional file 2).
In patients receiving anti-acid medication at baseline,
mean (SD) duration of exposure to study medication
was 10.1 (3.5) months in the nintedanib group and 10.7
(2.8) months in the placebo group. In patients not re-
ceiving anti-acid medication at baseline, mean (SD) dur-
ation of exposure in these groups was 10.4 (3.3) months
and 10.9 (2.8) months, respectively.
Annual rate of decline in FVC
In the evaluation of whether there was a difference in
the natural course of IPF by anti-acid medication use at
baseline, the adjusted annual rate of decline in FVC was
− 252.9 mL/year in placebo-treated patients who were
receiving anti-acid medication at baseline and −
205.4 mL/year in placebo-treated patients who were not
receiving anti-acid medication at baseline (difference of
− 47.5 mL/year [95% CI: –105.1, 10.1]; p = 0.1057).
In analyses to investigate the potential influence of
anti-acid medication use at baseline on the treatment ef-
fect of nintedanib, the adjusted annual rates of decline
in FVC were − 124.4 mL/year in the nintedanib group
and − 252.9 mL/year in the placebo group (difference of
Table 1 Baseline characteristics
Anti-acid medication at baseline No anti-acid medication at baseline
Nintedanib (n = 244) Placebo (n = 162) Nintedanib (n = 394) Placebo (n = 261)
Age, years, mean (SD) 67.4 (8.3) 68.0 (7.4) 66.1 (8.0) 66.4 (8.1)
Male, n (%) 179 (73.4) 124 (76.5) 328 (83.2) 210 (80.5)
Race, n (%)
White 164 (67.2) 117 (72.2) 196 (49.7) 131 (50.2)
Asian 40 (16.4) 28 (17.3) 154 (39.1) 100 (38.3)
Black 0 (0.0) 0 (0.0) 2 (0.5) 0 (0.0)
Missing* 40 (16.4) 17 (10.5) 42 (10.7) 30 (11.5)
Former or current smoker, n (%) 170 (69.7) 121 (74.7) 294 (74.6) 180 (69.0)
FVC, mL, mean (SD) 2643 (712) 2679 (818) 2757 (781) 2758 (806)
FVC, % predicted, mean (SD) 80.3 (17.4) 78.4 (17.3) 79.4 (17.7) 79.8 (18.8)
FEV1/FVC, %, mean (SD) 82.0 (5.5) 81.9 (5.9) 81.4 (6.1) 81.5 (6.0)
DLco, % predicted, mean (SD) 47.6 (15.1) 48.1 (14.3) 47.3 (12.4) 46.3 (12.8)
SGRQ total score, mean (SD)† 43.4 (18.7) 44.1 (17.9) 37.2 (19.1) 36.8 (18.4)
*In France, regulation did not permit the collection of data on race. †n = 234 for nintedanib and n = 160 for placebo in anti-acid medication at baseline subgroup;
n = 390 for nintedanib and n = 259 for placebo in no anti-acid medication at baseline subgroup
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128.6 mL/year [95% CI: 74.9, 182.2]) in patients who
were receiving anti-acid medication at baseline and −
107.0 mL/year in the nintedanib group and − 205.3 mL/
year in the placebo group (difference of 98.3 mL/year
[95% CI: 54.1, 142.5]) in patients who were not (Fig. 1).
There was no significant treatment-by-time-by-subgroup
interaction (p = 0.3869), indicating that the treatment ef-
fect was the same in both subgroups (Fig. 1).
Disease progression
There was a numerical but not significant difference in
the time to absolute decline in FVC ≥10% predicted or
death between placebo-treated patients who were taking
anti-acid medication at baseline versus were not receiv-
ing anti-acid medication at baseline (HR 1.33 [95% CI:
0.98, 1.80]; p = 0.0661). In total, 47.5% and 37.5% of
placebo-treated patients who were and were not receiv-
ing anti-acid medication at baseline, respectively, had a
decline in FVC ≥10% predicted or died, while 75.3% and
69.3% of placebo-treated patients in these subgroups, re-
spectively, had a decline in FVC ≥5% predicted or died.
In analyses to investigate the potential influence of
anti-acid medication use at baseline on the treatment ef-
fect of nintedanib, the HRs for time to decline in FVC
≥10% predicted or death were 0.60 (95% CI: 0.43, 0.82)
in patients who were receiving anti-acid medication at
baseline and 0.60 (95% CI: 0.45, 0.79) in patients who
were not (treatment-by-subgroup interaction p = 0.9808).
The HRs for time to decline in FVC ≥5% predicted or
death were 0.61 (95% CI: 0.48, 0.78) and 0.60 (95% CI:
0.49, 0.73) in these groups, respectively (treatment-by-
subgroup interaction p = 0.8661). For both disease
progression endpoints, the criterion reached was FVC
decline rather than death in most patients (Table 2).
Investigator-reported acute exacerbations
Kaplan-Meier estimates of time to first acute exacerbation
are presented in Fig. 2. In the placebo group, 19 patients
(11.7%) and 13 patients (5.0%) who were and were not re-
ceiving anti-acid medication at baseline, respectively, had
≥1 acute exacerbation. In the nintedanib group, 12 pa-
tients (4.9%) and 19 patients (4.8%) who were and were
not receiving anti-acid medication at baseline, respect-
ively, had ≥1 acute exacerbation. The HR for nintedanib
versus placebo for time to first acute exacerbation was
0.40 (95% CI: 0.19, 0.83) in patients who were receiving
anti-acid medication at baseline and 0.99 (95% CI: 0.49,
2.00) in patients who were not. Although there was no sig-
nificant treatment-by-subgroup interaction (p = 0.0949),
there appeared to be a numerical difference, not ruling
out a potential difference in the treatment effect of ninte-
danib between the subgroups.
SGRQ total score
In the placebo group, the adjusted mean changes from
baseline in SGRQ total score over 52 weeks were 6.54
and 4.04 in patients who were and were not receiving
anti-acid medication at baseline, respectively; in the nin-
tedanib group, the adjusted mean changes from baseline
were 4.83 and 2.80 in these subgroups, respectively
(Fig. 3). There was no significant treatment-by-subgroup
interaction (p = 0.8536), indicating that the treatment ef-
fect was the same in both subgroups.
-124.4
-107.0
-252.9
-205.3
-300
-250
-200
-150
-100
-50
0 ni enilced fo )
E
S( etar launna detsujd
A
)raey/L
m( 
C
V
F
Nintedanib Placebo
Treatment-by-time-by-
subgroup interaction 
p=0.3869
 128.6 mL 
(95% CI: 74.9, 182.2)
Anti-acid medication 
at baseline
98.3 mL
(95% CI: 54.1, 142.5)
n=244 n=162 n=394 n=261
No anti-acid medication 
at baseline
Fig. 1 Annual rate of decline in FVC
Costabel et al. Respiratory Research  (2018) 19:167 Page 4 of 9
Adverse events
A summary of adverse events is presented in Table 3.
Diarrhea was the most frequent adverse event in
nintedanib-treated patients, reported in 60.7% and 63.5% of
patients who were and were not receiving anti-acid medica-
tion at baseline compared with 17.3% and 19.2% of
placebo-treated patients in these groups, respectively. Per-
manent discontinuation of study medication due to diarrhea
was more frequent in nintedanib-treated patients who were
receiving anti-acid medication at baseline than those were
not (6.6% versus 3.0%). Pneumonia was reported in 5.3%
and 7.4% of nintedanib- and placebo-treated patients who
were receiving anti-acid medication at baseline compared
with 4.1% and 4.6% of nintedanib- and placebo-treated pa-
tients who were not, respectively. Serious adverse events
were reported in 35.7% and 37.0% of nintedanib- and
placebo-treated patients who were receiving anti-acid medi-
cation at baseline compared with 27.2% and 25.7% of ninte-
danib- and placebo-treated patients who were not,
respectively (Additional file 3).
Table 2 Disease progression
N (%) Anti-acid medication at baseline No anti-acid medication at baseline
Nintedanib (n = 244) Placebo (n = 162) Nintedanib (n = 394) Placebo (n = 261)
Absolute decline in FVC ≥10% predicted or death 77 (31.6) 77 (47.5) 96 (24.4) 98 (37.5)
Criterion reached first
Absolute decline in FVC ≥10% predicted 67 (27.5) 65 (40.1) 81 (20.6) 88 (33.7)
Death 10 (4.1) 12 (7.4) 15 (3.8) 10 (3.8)
Absolute decline in FVC ≥5% predicted or death 135 (55.3) 122 (75.3) 195 (49.5) 181 (69.3)
Criterion reached first
Absolute decline in FVC ≥5% predicted 129 (52.9) 117 (72.2) 188 (47.7) 175 (67.0)
Death 6 (2.5) 5 (3.1) 7 (1.8) 6 (2.3)
Time to first acute exacerbation
No. of patients
Anti-acid medication at baseline –
nintedanib
244 240 238 234 232 229 225 224 223 218 214 211 202 182
No anti-acid medication at baseline –
nintedanib
394 392 389 375 373 366 364 360 357 352 348 342 335 310
Anti-acid medication at baseline –
placebo
162 160 160 155 155 154 151 148 146 142 140 136 130 122
Anti-acid medication at baseline – placebo
Anti-acid medication at baseline – nintedanib
No anti-acid medication at baseline – nintedanib
No anti-acid medication at baseline – placebo
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Discussion
The results of this post-hoc subgroup analysis of data
from the INPULSIS® trials showed that use of anti-acid
medication at baseline generally did not influence the
treatment effect of nintedanib in patients with IPF. In
the placebo group, the annual rate of decline in FVC
was numerically higher in patients who were receiving
anti-acid medication at baseline than in those who were
not (− 252.9 vs − 205.4 mL/year; difference of −
47.5 mL/year [95% CI: –105.1, 10.1]; p = 0.1057) and a
greater proportion of patients receiving anti-acid medi-
cation at baseline experienced decline in FVC ≥10% pre-
dicted or died over 52 weeks (47.5% vs 37.5%). These
findings should be interpreted with caution given that
these analyses were conducted post-hoc; that patients
were not randomized according to reported use of
anti-acid medication; that information on the type, dose,
and duration of anti-acid medication used throughout
(or prior to) the study are lacking; that the efficacy of
anti-acid medication in suppressing acid reflux is not
known, and that it is unknown whether the patients
were taking anti-acid medication to treat symptomatic
GERD (acid or non-acid), assumed silent GERD, or even
IPF. Similar caveats apply to the interpretation of data
from a post-hoc analysis of pooled data from three ran-
domized trials of pirfenidone in patients with IPF, in
which use of anti-acid therapy at baseline was not asso-
ciated with a difference in the occurrence of disease pro-
gression in either the placebo group [18, 23] or the
pirfenidone group [24].
Elevated pepsin levels in bronchoalveolar lavage fluid
have been documented in patients manifesting acute ex-
acerbations of IPF [8]. In a prospective observational
study of data from placebo-treated patients with IPF in
the IPFnet trials, there were no adjudicated acute exacer-
bations in the 124 patients who used anti-acid medica-
tion at baseline (of whom 117 continued to take it for
the entire study period) versus 9 acute exacerbations in
the 118 patients who did not use anti-acid medication at
baseline [15]. In contrast, in our post-hoc analysis of data
from the INPULSIS® trials, acute exacerbations reported
by the site investigators occurred in a greater proportion
of placebo-treated patients who were receiving anti-acid
medication at baseline than in those who were not
(11.7% [19 patients] versus 5.0% [13 patients]). An in-
creased risk of investigator-reported acute exacerbations
(and adjudicated confirmed or suspected acute exacerba-
tions) was also observed in a risk factor analysis based
on pooled data from these trials [25]. There are multiple
hypotheses that may explain these findings. Patients who
were receiving anti-acid medication at baseline may have
had a greater extent of IPF than patients who were not.
The patients receiving anti-acid medication at baseline
had worse health-related quality of life at baseline ac-
cording to SGRQ total score and a greater frequency of
fatal adverse events, but did not have greater lung func-
tion impairment based on FVC or DLco. Secondly, it is
possible that the increased frequency of acute exacerba-
tions in patients taking anti-acid medication at baseline
may be due to insufficiently controlled microaspiration
in patients who had co-existing GERD. Abnormal acid
gastro-oesphageal reflux has been documented in pa-
tients with IPF taking proton pump inhibitors [26], and
the use of antiacid medication may not have fully sup-
pressed acid reflux in patients in these trials who had
concomitant GERD. Thirdly, it may be hypothesized that
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patients receiving anti-acid medication at baseline were
at greater risk of infectious respiratory events (e.g. pneu-
monia) due to altered host defense against bacteria as a
result of increased gastric pH. In our analysis, pneumo-
nia was reported in a numerically higher proportion of
placebo-treated patients receiving anti-acid medication
at baseline than placebo-treated patients who were not.
Epidemiological data suggest a potential adverse rela-
tionship between proton pump inhibitor use and com-
munity acquired pneumonia [27–29], and a post-hoc
analysis of data from placebo-treated patients in trials of
pirfenidone suggested that in patients with FVC < 70%
predicted at baseline, unadjudicated pulmonary infec-
tions were more common in patients who were taking
anti-acid medication at baseline [18, 19, 23].
The proportion of patients experiencing diarrhea ad-
verse events was similar in the subgroups by anti-acid
medication use at baseline, but in the nintedanib group,
the frequency of permanent treatment discontinuations
due to diarrhea, although low, was numerically higher in
patients receiving anti-acid medication at baseline. Over-
all, the adverse event profile of nintedanib in patients in
both subgroups by anti-acid medication use was as ex-
pected based on the safety and tolerability profile re-
ported in the overall patient population [22].
Conclusion
In conclusion, this post-hoc analysis of data from the
INPULSIS® trials showed that anti-acid medication use
at baseline was not associated with a more favorable
course of disease, and did not impact the treatment ef-
fect of nintedanib, in patients with IPF. Several hypoth-
eses generated from this data warrant additional
research, including prospective randomized clinical tri-
als, to determine the role of acid and non-acid GERD in
patients with interstitial lung diseases such as IPF and to
Table 3 Adverse events
Anti-acid medication at baseline No anti-acid medication at baseline
Nintedanib (n = 244) Placebo (n = 162) Nintedanib (n = 394) Placebo (n = 261)
Any adverse event(s) 235 (96.3) 152 (93.8) 374 (94.9) 227 (87.0)
Most frequent adverse event(s)*
Diarrhea 148 (60.7) 28 (17.3) 250 (63.5) 50 (19.2)
Nausea 66 (27.0) 14 (8.6) 90 (22.8) 14 (5.4)
Nasopharyngitis 32 (13.1) 24 (14.8) 55 (14.0) 44 (16.9)
Cough 41 (16.8) 29 (17.9) 44 (11.2) 28 (10.7)
Vomiting 36 (14.8) 4 (2.5) 38 (9.6) 7 (2.7)
Decreased appetite 27 (11.1) 9 (5.6) 41 (10.4) 15 (5.7)
Bronchitis 35 (14.3) 18 (11.1) 32 (8.1) 27 (10.3)
Progression of IPF† 28 (11.5) 30 (18.5) 36 (9.1) 31 (11.9)
Weight decreased 26 (10.7) 5 (3.1) 36 (9.1) 10 (3.8)
Upper respiratory tract infection 20 (8.2) 18 (11.1) 38 (9.6) 24 (9.2)
Dyspnea 23 (9.4) 22 (13.6) 26 (6.6) 26 (10.0)
Headache 25 (10.2) 8 (4.9) 18 (4.6) 11 (4.2)
Serious adverse event(s)‡ 87 (35.7) 60 (37.0) 107 (27.2) 67 (25.7)
Severe adverse event(s)§ 84 (34.4) 44 (27.2) 90 (22.8) 55 (21.1)
Fatal adverse event(s) 20 (8.2) 15 (9.3) 17 (4.3) 16 (6.1)
Adverse event(s) leading to treatment discontinuation¶ 57 (23.4) 26 (16.0) 66 (16.8) 29 (11.1)
Diarrhea 16 (6.6) 0 (0.0) 12 (3.0) 1 (0.4)
Progression of IPF† 5 (2.0) 12 (7.4) 8 (2.0) 9 (3.4)
Nausea 4 (1.6) 0 (0.0) 9 (2.3) 0 (0.0)
Pneumonia 5 (2.0) 1 (0.6) 1 (0.3) 0 (0.0)
Data shown are n(%) of patients in whom ≥1 such event was reported
*Adverse events reported in ≥10% of patients in any of the subgroups shown
†Corresponds to Medical Dictionary for Regulatory Activities (MedDRA) term ‘IPF’, which included disease worsening and acute exacerbations of IPF
‡An event that resulted in death, was immediately life-threatening, resulted in persistent or clinically significant disability or incapacity, required or prolonged
hospitalization, was related to a congenital anomaly or birth defect, or was deemed serious for any other reason
§An event that was incapacitating or that caused an inability to work or to perform usual activities
¶Adverse events leading to treatment discontinuation in ≥2% of patients in any of the subgroups shown
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characterize the benefits and risks of anti-acid medica-
tion in these patients. Further, the results of the
WRAP-IPF trial (NCT01982968) will provide insights
regarding the effects of laparoscopic anti-reflux surgery
in patients with IPF.
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